相关实验视频

Updated: May 13, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

化学耐药三阴性乳腺癌亚型的表征和向,使用氨基胺化合物

Santiago Ruiz-Martínez¹, Xavi Ribas², Miquel Costas²

¹New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Spain; Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, Sahlgrenska Center for Cancer Research, University of Gothenburg, Sweden.

Biochimica et biophysica acta. Molecular basis of disease

|May 11, 2025

概括

三重阴性乳腺癌 (TNBC) 是异质的,耐治疗的. 新型化合物在减少癌症干细胞和提高对TNBC的化疗疗效率方面表现有前途.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

三重阴性乳腺癌 (TNBC) 由于其异质性,化学抵抗性和癌症干细胞 (CSC) 存在重大治疗挑战.
了解TNBC亚型及其耐药变体的分子基础对于开发有效治疗非常重要.

研究的目的:

描述两个不同的TNBC细胞系 (MDA-MB-231和HCC1806) 和它们的抗化学性衍生物的分子形状和侵入性特性.
研究CSC标记物的作用,上皮细胞-介质细胞过渡 (EMT) 和胚胎信号通路在TNBC化学抵抗中的作用.
评估新型聚胺化合物对敏感和耐药TNBC细胞和CSCs的治疗潜力.

主要方法:

对两种TNBC细胞系 (MDA-MB-231,HCC1806) 和它们的抗多克索鲁比/帕克利塔塞尔变体进行比较分析.
评估癌症干细胞标记物 (CD44,CD24,CD133),EMT标记物和阿尔代脱酶 (ALDH) 活性.
对胚胎信号通路的分析,包括Sonic Hedgehog和Notch.
在实验室中评估新型氨基胺聚胺化合物对细胞毒性,CSC性质的降低和标准化疗剂的增强.

主要成果:

TNBC细胞系表现出明显的EMT标志物概况和CSC特征 (CD44+/CD24-/低).
耐化学药的变种显示出改变的CSC标记物 (特别是CD133上调),EMT基因表达和ALDH活性.
在BL2亚型中,Sonic Hedgehog信号突出,耐药模型显示了增加的Notch受体表达.
新型聚胺化合物对敏感和耐药的TNBC细胞表现出显著的细胞毒性,降低了CSC自我更新,并强化了标准化疗.

结论:

TNBC表现出显著的分子异质性,影响化学抵抗和CSC特性.
CD133,Sonic Hedgehog和Notch信号通路都与TNBC化学抵抗有关.
新型聚胺化合物代表了一种有前途的治疗策略,以克服TNBC化学抵抗并向CSC,增强当前的治疗方案.

关键词:

氨基二烯化合物是一种氨基二烯化合物.癌症干细胞 (CSCs) 是一种癌症干细胞.化学抗药性化学抗药性是一种抗药性.三重阴性乳腺癌 (TNBC) 是一种

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...